We found that GSTP1 IIe105Val, GSTM1 and GSTT1 null genetic polymorphisms might be predictive factors for the efficacy of platinum-based chemotherapy to NSCLC patients. The gene discussed is GSTM1; the disease is non-small cell lung carcinoma.